Abbisko and Eli Lilly Forge $1.9B R&D Collaboration
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 53 minutes ago
0mins
Source: seekingalpha
- Collaboration Overview: Abbisko Therapeutics, a Chinese drug developer, has entered into a $1.9 billion R&D and licensing collaboration with Eli Lilly, aimed at developing novel therapies for multiple disease targets, showcasing a powerful alliance in innovative drug development.
- Utilization of R&D Platform: Under the agreement, Abbisko will leverage its early-stage drug discovery platform and R&D expertise to discover and conduct early research on drugs against targets selected by Eli Lilly, enhancing Abbisko's R&D capabilities while providing Eli Lilly with new therapeutic options.
- Milestone Payment Structure: Abbisko will receive an upfront payment along with up to $1.9 billion in milestone payments contingent upon the achievement of development, regulatory, and commercial goals, indicating Eli Lilly's strong recognition of Abbisko's research potential.
- Strategic Partnership Continuation: This collaboration builds on a global partnership and exclusive licensing deal signed in 2022 between Abbisko and Eli Lilly, further solidifying their strategic partnership in small-molecule drug development and signaling potential market expansion in the future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1102.080
Low
950.00
Averages
1192
High
1500
Current: 1102.080
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Grants Access to Eli Lilly's Next-Gen Obesity Drug for 79-Year-Old Patient
- FDA Collaboration: The FDA has partnered with Eli Lilly (LLY) to allow a 79-year-old man to access the experimental obesity drug retatrutide through the compassionate use program, highlighting the agency's support for innovative therapies.
- Significant Drug Efficacy: Retatrutide targets GIP, GLP-1, and glucagon receptors, with late-stage trial data indicating up to 28% weight loss over 80 weeks in adults with obesity or overweight, showcasing its potential as a powerful weight-loss solution.
- Unique Patient Background: The patient, aged 79 at the time of the request in April, was reportedly well-connected, suggesting that his application for FDA approval was influenced by high-level health officials, which may impact the drug's future accessibility.
- Transparent Company Policy: Eli Lilly stated that it provides investigational medicines in rare cases when individuals cannot join clinical trials and have exhausted treatment options, demonstrating the company's commitment to addressing patient needs and regulatory compliance.
See More
Sangamo Therapeutics Enters Asset Sales and Bankruptcy Proceedings
- Asset Sale Agreements: Sangamo Therapeutics has entered into agreements with Eli Lilly to sell its capsid delivery platform, zinc finger platform, modular integrase platform, and the ST-506 program, which is expected to generate cash flow to support its reorganization efforts.
- Transaction with Astellas: Concurrently, Sangamo has also reached an agreement with Astellas Pharma to sell the Fabry disease program, isaralgagene civaparvovec (ST-920), further optimizing its asset structure and focusing on core business areas.
- Bankruptcy Reorganization Initiation: Sangamo has voluntarily filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware, aiming to facilitate a court-supervised reorganization that includes the auction of nearly all its assets to address financial distress and rebuild the company.
- Stalking Horse Bidders: Eli Lilly and Astellas will serve as stalking horse bidders for the asset sale, indicating their strategic interest in Sangamo's technologies and assets, potentially laying the groundwork for future collaborations.
See More
Abbisko and Eli Lilly Forge $1.9B R&D Collaboration
- Collaboration Overview: Abbisko Therapeutics, a Chinese drug developer, has entered into a $1.9 billion R&D and licensing collaboration with Eli Lilly, aimed at developing novel therapies for multiple disease targets, showcasing a powerful alliance in innovative drug development.
- Utilization of R&D Platform: Under the agreement, Abbisko will leverage its early-stage drug discovery platform and R&D expertise to discover and conduct early research on drugs against targets selected by Eli Lilly, enhancing Abbisko's R&D capabilities while providing Eli Lilly with new therapeutic options.
- Milestone Payment Structure: Abbisko will receive an upfront payment along with up to $1.9 billion in milestone payments contingent upon the achievement of development, regulatory, and commercial goals, indicating Eli Lilly's strong recognition of Abbisko's research potential.
- Strategic Partnership Continuation: This collaboration builds on a global partnership and exclusive licensing deal signed in 2022 between Abbisko and Eli Lilly, further solidifying their strategic partnership in small-molecule drug development and signaling potential market expansion in the future.
See More
Illumina Appoints New Board Member
- New Board Appointment: Illumina announced the appointment of Daniel M. Skovronsky to its Board of Directors, effective June 16, 2026, with his extensive experience in drug discovery and clinical development expected to provide strategic advantages for the company.
- Industry Background: Skovronsky currently serves as Chief Scientific and Product Officer at Eli Lilly and President of Lilly Research Laboratories, and his expertise is anticipated to aid Illumina's further development in the biotechnology sector.
- Previous Roles: Prior to this, Skovronsky was a board member at Myriad Genetics and founded Avid Radiopharmaceuticals in 2004, serving as CEO, showcasing his deep roots in the biopharmaceutical industry.
- Stock Performance: Illumina closed Tuesday's trading at $164.93, up 2.20%, and this positive market reaction may be linked to the strategic significance of the new appointment, reflecting investor confidence in the company's future growth.
See More
Eli Lilly's Orforglipron Diabetes Pill Could Launch in China Soon
- Intensifying Market Competition: Eli Lilly's orforglipron, an oral diabetes and obesity medication, is expected to launch in China between late 2026 and early 2027, facing competition from Novo Nordisk, which has received early approvals in the U.S. and U.K., highlighting the fierce competition in the global pharmaceutical industry.
- Regulatory Application Progress: Lilly submitted a marketing application for orforglipron to China's National Medical Products Administration at the end of 2025, marking a strategic move into the Chinese market aimed at meeting the demand for non-injection weight-loss medications.
- Sales Channel Strategy: Lilly plans to sell orforglipron through existing partnerships with Chinese e-commerce and healthcare firms like Alibaba and JD Health International, ensuring market coverage and accessibility, thereby enhancing its competitive edge in China.
- Market Potential Assessment: Although the market share for weight-loss drugs in China remains unclear, Jefferies reported that GLP-1 treatment sales through Alibaba and JD.com reached approximately 1.4 billion yuan ($207 million) in Q1 2023, indicating significant market potential.
See More
Abbisko and Eli Lilly Enter Strategic Collaboration
- Strategic Collaboration: Abbisko Therapeutics has entered into a strategic research collaboration and license agreement with Eli Lilly to leverage Abbisko's early-stage drug discovery platform for developing medicines targeting multiple disease areas, thereby accelerating drug development and enhancing market competitiveness.
- Continuation of Historical Partnership: This collaboration builds on the global partnership and exclusive licensing agreement established in 2022, indicating a long-term strategic consensus between the two companies in the small-molecule therapeutics space, which will facilitate the rapid market entry of innovative drugs.
- Product Development Progress: Abbisko is advancing its small-molecule CSF-1R inhibitor Pimicotinib (ABSK021) into the NDA stage for treating tenosynovial giant cell tumors, and successful approval could significantly increase the company's market share in oncology treatments.
- Stock Performance: Abbisko's stock is currently trading at HK$9.31, up 3.44% from the previous trading day, reflecting positive market sentiment regarding its collaboration prospects, while Eli Lilly's stock is up 0.45% at $1107.08, indicating investor confidence in its continued growth potential.
See More
FDA Grants Access to Eli Lilly's Next-Gen Obesity Drug for 79-Year-Old Patient
- FDA Collaboration: The FDA has partnered with Eli Lilly (LLY) to allow a 79-year-old man to access the experimental obesity drug retatrutide through the compassionate use program, highlighting the agency's support for innovative therapies.
- Significant Drug Efficacy: Retatrutide targets GIP, GLP-1, and glucagon receptors, with late-stage trial data indicating up to 28% weight loss over 80 weeks in adults with obesity or overweight, showcasing its potential as a powerful weight-loss solution.
- Unique Patient Background: The patient, aged 79 at the time of the request in April, was reportedly well-connected, suggesting that his application for FDA approval was influenced by high-level health officials, which may impact the drug's future accessibility.
- Transparent Company Policy: Eli Lilly stated that it provides investigational medicines in rare cases when individuals cannot join clinical trials and have exhausted treatment options, demonstrating the company's commitment to addressing patient needs and regulatory compliance.
See More
Sangamo Therapeutics Enters Asset Sales and Bankruptcy Proceedings
- Asset Sale Agreements: Sangamo Therapeutics has entered into agreements with Eli Lilly to sell its capsid delivery platform, zinc finger platform, modular integrase platform, and the ST-506 program, which is expected to generate cash flow to support its reorganization efforts.
- Transaction with Astellas: Concurrently, Sangamo has also reached an agreement with Astellas Pharma to sell the Fabry disease program, isaralgagene civaparvovec (ST-920), further optimizing its asset structure and focusing on core business areas.
- Bankruptcy Reorganization Initiation: Sangamo has voluntarily filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware, aiming to facilitate a court-supervised reorganization that includes the auction of nearly all its assets to address financial distress and rebuild the company.
- Stalking Horse Bidders: Eli Lilly and Astellas will serve as stalking horse bidders for the asset sale, indicating their strategic interest in Sangamo's technologies and assets, potentially laying the groundwork for future collaborations.
See More
Abbisko and Eli Lilly Forge $1.9B R&D Collaboration
- Collaboration Overview: Abbisko Therapeutics, a Chinese drug developer, has entered into a $1.9 billion R&D and licensing collaboration with Eli Lilly, aimed at developing novel therapies for multiple disease targets, showcasing a powerful alliance in innovative drug development.
- Utilization of R&D Platform: Under the agreement, Abbisko will leverage its early-stage drug discovery platform and R&D expertise to discover and conduct early research on drugs against targets selected by Eli Lilly, enhancing Abbisko's R&D capabilities while providing Eli Lilly with new therapeutic options.
- Milestone Payment Structure: Abbisko will receive an upfront payment along with up to $1.9 billion in milestone payments contingent upon the achievement of development, regulatory, and commercial goals, indicating Eli Lilly's strong recognition of Abbisko's research potential.
- Strategic Partnership Continuation: This collaboration builds on a global partnership and exclusive licensing deal signed in 2022 between Abbisko and Eli Lilly, further solidifying their strategic partnership in small-molecule drug development and signaling potential market expansion in the future.
See More
Illumina Appoints New Board Member
- New Board Appointment: Illumina announced the appointment of Daniel M. Skovronsky to its Board of Directors, effective June 16, 2026, with his extensive experience in drug discovery and clinical development expected to provide strategic advantages for the company.
- Industry Background: Skovronsky currently serves as Chief Scientific and Product Officer at Eli Lilly and President of Lilly Research Laboratories, and his expertise is anticipated to aid Illumina's further development in the biotechnology sector.
- Previous Roles: Prior to this, Skovronsky was a board member at Myriad Genetics and founded Avid Radiopharmaceuticals in 2004, serving as CEO, showcasing his deep roots in the biopharmaceutical industry.
- Stock Performance: Illumina closed Tuesday's trading at $164.93, up 2.20%, and this positive market reaction may be linked to the strategic significance of the new appointment, reflecting investor confidence in the company's future growth.
See More
Eli Lilly's Orforglipron Diabetes Pill Could Launch in China Soon
- Intensifying Market Competition: Eli Lilly's orforglipron, an oral diabetes and obesity medication, is expected to launch in China between late 2026 and early 2027, facing competition from Novo Nordisk, which has received early approvals in the U.S. and U.K., highlighting the fierce competition in the global pharmaceutical industry.
- Regulatory Application Progress: Lilly submitted a marketing application for orforglipron to China's National Medical Products Administration at the end of 2025, marking a strategic move into the Chinese market aimed at meeting the demand for non-injection weight-loss medications.
- Sales Channel Strategy: Lilly plans to sell orforglipron through existing partnerships with Chinese e-commerce and healthcare firms like Alibaba and JD Health International, ensuring market coverage and accessibility, thereby enhancing its competitive edge in China.
- Market Potential Assessment: Although the market share for weight-loss drugs in China remains unclear, Jefferies reported that GLP-1 treatment sales through Alibaba and JD.com reached approximately 1.4 billion yuan ($207 million) in Q1 2023, indicating significant market potential.
See More
Abbisko and Eli Lilly Enter Strategic Collaboration
- Strategic Collaboration: Abbisko Therapeutics has entered into a strategic research collaboration and license agreement with Eli Lilly to leverage Abbisko's early-stage drug discovery platform for developing medicines targeting multiple disease areas, thereby accelerating drug development and enhancing market competitiveness.
- Continuation of Historical Partnership: This collaboration builds on the global partnership and exclusive licensing agreement established in 2022, indicating a long-term strategic consensus between the two companies in the small-molecule therapeutics space, which will facilitate the rapid market entry of innovative drugs.
- Product Development Progress: Abbisko is advancing its small-molecule CSF-1R inhibitor Pimicotinib (ABSK021) into the NDA stage for treating tenosynovial giant cell tumors, and successful approval could significantly increase the company's market share in oncology treatments.
- Stock Performance: Abbisko's stock is currently trading at HK$9.31, up 3.44% from the previous trading day, reflecting positive market sentiment regarding its collaboration prospects, while Eli Lilly's stock is up 0.45% at $1107.08, indicating investor confidence in its continued growth potential.
See More
